SCARLETRED is presenting the results of their latest publication at the 32nd EADV Congress in Berlin, Germany. The study examined the use of deep learning algorithms for erythema scoring in radiation-induced dermatitis.

The 7th Dermatology Drug Development Summit in Boston, USA, for inflammatory skin diseases presents novel therapeutics for rare and common skin diseases such as Atopic Dermatitis, Hidradenitis suppurativa, and more.

Striving to develop and expand Scarletred®Vision’s telemedicine applications, we are happy to invite medical doctors to join our Discovery Program to include our software in clinical routine procedures free of cost.

President of the European Patent Office Mariana Karepova shares her insights into the world of innovations and ideas while being president at the Austrian patent office and Scarletred being her favorite one in the last years.

Scarletred cooperates with the Seestadt Apotheke to provide customers AI-based personalized skin care consultations and further education about preventing skin diseases, cancer, and ageing caused by exposure to UV rays.

The study uses photobiomodulation at different wavelengths for wound care in diabetic wounds and resulted in signficant positive effects objectively shown by the medical device software Scarletred®Vision.

In the B&C Group's podcast Über:Mut, Scarletred's CEO Harald Schnidar discusses together with Mariana Karepova, President of the Austrian Patent Office, the protection and potential of innovations in Austria.

Scarletred’s CEO Harald Schnidar joins the Dermatology Drug Development Summit 2023 Europe in Berlin, Germany, to speak on the topic of AI-assisted objective skin imaging and analysis.

Topical Bimiralisib, used in patients with the rare cutaneous form of T-cell lymphoma, known as Mycosis fungoides, and healthy patients, showed substantial results regarding cutaneous drug levels.

Our CEO Harald Schnidar is invited to present the results of a cooperation with GALDERMA and the University of Tübingen, wherein Scarletred®Vision confirmed the therapeutic efficacy of Ivermectin in Rosacea patients.

Discover our newest publication about Ivermectin treatment in rosacea patients in cooperation with the university clinic Tübingen, Germany, and how Scarletred®Vision helped monitor signs and symptoms. 

Die Seestadt Apotheke in 1220, Wien, lädt zu ihrem kosmetischen Beratungstag am 29.11.2022 ein. Unterstützt durch Produkte von Eucerin, wird Scarletred exklusiv helfen den Hautzustand zu erfassen und analysieren.

The 6th Dermatology Drug Development Summit for inflammatory skin diseases gives insight into novel therapeutics and patient-specific and alternative treatment options currently in clinical trials for various skin diseases.

The life science and pharmaceutical fair takes place October 11-14th to bring together innovative companies, customers, and investors. SCARLETRED is one of nine companies representing the Austrian Economic Chambers in Tokyo.

Our published paper about machine learning and developing the SEV value will be presented at the ÖGRO annual congress in Villach, Austria, with our collaborator at the Landeskrankenhaus Graz, Dr. Richard Partl.

​​SCARLETRED is visiting and presenting at this year´s 51st Annual ESDR Summit taking place in Amsterdam, Netherlands between 28th September - 1st October 2022.

SCARLETRED visits the hybrid EADV congress in Milan from September 7-9, 2022, to present the results of a new rosacea study that used Scarletred®Vision to measure the effectiveness of a new treatment.

We are excited to announce that SCARLETRED has received a new EC declaration of conformity approving Scarletred®Vision as a physiological measuring system and a CE Class 1m medical device.

After 3 years, the well-renowned women's conference, Global Female Leaders Summit, will take place from the 8th-10th of May 2022 at the Adlon Hotel Kempinski in Berlin, Germany.

Post-Marketing Studies play an integral role in gathering information about safety and efficacy on a large scale. However, monitoring adverse events and patient-reported outcomes in a real-world setting can be challenging.

A study, performed by the Medical University of Vienna, examined diagnostic accuracy of SARS-CoV-2 rapid antigen tests compared to RT-PCR as the gold standard based on different swab sites by using Scarletred®Vision.

Following a successful launch in Europe in 2019, and a tremendous online experience in 2021, the 3rd Dermatology Drug Development Europe Summit, returns in April 2022 in Frankfurt, Germany.

The DP aims to collaborate with pharmaceutical and biotechnology companies by providing access to our customizable software Scarletred®Vision for exploratory or early-stage clinical studies at a more attractive price point.

SCARLETRED is currently featured at the Arab Health 2022 exhibition in Dubai, among other companies in medical and healthcare-related categories. The networking event helps to connect and support innovations in healthcare.

The EXPO 2020 “Connecting Minds, Creating the Future” theme addresses visions of a networked and technology-based future. SCARLETRED is currently exhibited in the iLab section representing the future of digital healthcare.

The business magazine Gewinn discusses how Scarletred®Vision is an excellent addition to the safety and monitoring of injection site reactions (ISRs) in vaccine development.

The national platform IÖB (public procurement promoting innovation) announced Austria’s top innovations. This year, the IÖB awarded SCARLETRED with Scarletred®Vision as a digital healthcare management solution.

The popular newspaper Der Standard features the recent milestones of SCARLETRED in the field of teledermatology. With these, SCARLETRED sets the benchmark for AI-Assisted Screening in telemedicine and radiation oncology.

In an interview, specialist Dr. Zikeli discusses the clinical characteristics of atopic dermatitis and why documentation using Scarletred®Vision is an optimal support for diagnosis and progress monitoring.

The 5th Annual Dermatology Drug Development Summit focusing on development and innovation of therapies and research targeting inflammatory skin diseases, returns to Boston for 2021.

The Inflammatory Skin Disease Summit is a jointly organized event by the Icahn School of Medicine at Mount Sinai and the Austrian Academy of Sciences.

The clinically validated and award-winning technology, Scarletred®Vision, is on market since 2015, enabling high quality remote skin imaging and objective analysis in over 3000 cutaneous disorders.

​​In the round table discussion of the leading financial domain Börse Express, Marinomed, Scarletred, PHH Rechtsanwälte, and EOSS Industries discussed the development and hurdles of Austrian life science start-ups.

The EXPO 2020 “Connecting Minds, Creating the Future” theme addresses visions of a more networked and technology-based future, covering topics from smart city over sustainability to digital healthcare.

International team of four talented students has won a 3rd place on WSA Youth for Innovation case study competition by solving Scarletred´s challenge on injection site reactions.

The research award has been awarded annually by the B&C Private Foundation. With the Houska Prize, the B&C private foundation is committed to improving research conditions and cutting-edge research in Austria.

Wien (OTS) - Videokonferenzen, Home Schooling, Online-Yogastunden – die aktuelle Corona-Situation hat eindrücklich bewiesen, wie wichtig digitale Kommunikation für alle Lebensbereiche geworden ist.

SeneCura is currently using the CE-certified medical device of Scarletred in eleven care facilities, after which a roll-out to every SeneCura facilities in Austria is planned.

Der Houskapreis ist Österreichs größter privater Forschungspreis. Insgesamt 500.000 Euro vergibt die B&C Privatstiftung für Spitzenforschung aus Österreich.

Following a call from the City of Vienna for 5G use case entries in autumn 2019, Azoome and Scarletred, with A1 as their technology partner, have won awards for education and healthcare. Funded pilots will begin this year.

Last week SCARLETRED won the Japanese TechBIZKON – Digital Health beyond 2020 Award! We want to say thanks to the audience for their strong vote and to EDGEof for making this great digital health event possible.

In 2014, while conducting a clinical trial, Dr. Harald Schnidar percieved the need of a technology that allows to objectify dermatological assessments. Reacting to the lack of a suitable solution, he founded SCARLETRED.

The GEWINN YOUNG ENTREPRENEUR competition took place for the 30th time, there were about 1,000 first registrations, of which 300 were judged and we are happy to say that SCARLETRED was positioned 7th in the final 100!